公开(公告)号：US11642390B2

公开(公告)日：2023-05-09

申请号：US17167990

申请日：2021-02-04

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Panayiotis Stevis ,  Andrew J. Murphy ,  Jesper Gromada ,  Yonaton Ray ,  Jee H. Kim ,  Ivan B. Lobov

IPC: A61K39/395 ,  A61K38/22 ,  A61K38/08 ,  A61K38/10 ,  A61K47/64 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  C07K16/28 ,  C07K7/06 ,  C07K7/08 ,  C07K14/575 ,  C07K19/00 ,  C07K14/705 ,  C07K14/72 ,  A61P37/02 ,  A61P35/00 ,  A61K38/00 ,  C07K14/47 ,  C07K16/46

CPC classification number: A61K38/08 ,  A61K38/10 ,  A61K38/22 ,  A61K39/3955 ,  A61K47/64 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  C07K16/2869 ,  A61K38/00 ,  A61P35/00 ,  A61P37/02 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/575 ,  C07K14/705 ,  C07K14/72 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/74

Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

公开(公告)号：US20190218301A1

公开(公告)日：2019-07-18

申请号：US16328935

申请日：2017-08-29

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jesper Gromada ,  Haruka Okamoto ,  Stephen Jaspers ,  Joyce Harp

IPC: C07K16/28 ,  A61P3/10 ,  A61K38/16

CPC classification number: C07K16/2869 ,  A61K38/16 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61P3/10 ,  C07K16/26 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.

公开(公告)号：US20190202934A1

公开(公告)日：2019-07-04

申请号：US16360793

申请日：2019-03-21

Applicant: VIB VZW ,  UNIVERSITEIT GENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER

Inventor： Jan TAVERNIER ,  Sarah GERLO ,  Frank PEELMAN ,  Gilles UZE

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/32 ,  C07K14/545

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2319/00

Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

公开(公告)号：US20190144872A1

公开(公告)日：2019-05-16

申请号：US16256507

申请日：2019-01-24

Applicant: Innovative Targeting Solutions Inc.

Inventor： Michael Gallo ,  Jaspal Singh Kang ,  Craig Robin Pigott

IPC: C12N15/62 ,  C07K16/28 ,  C07K14/54 ,  C07K16/32 ,  C12N15/85 ,  C07K16/00 ,  C07K14/47 ,  C07K14/78 ,  C07K14/71 ,  C07K14/575 ,  C07K14/605 ,  C07K14/52

CPC classification number: C12N15/625 ,  C07K14/4723 ,  C07K14/522 ,  C07K14/5421 ,  C07K14/57563 ,  C07K14/605 ,  C07K14/71 ,  C07K14/78 ,  C07K16/00 ,  C07K16/2839 ,  C07K16/2866 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/565 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/03 ,  C12N15/62 ,  C12N15/85 ,  C12N2800/30

Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.

公开(公告)号：US20180362645A1

公开(公告)日：2018-12-20

申请号：US16017891

申请日：2018-06-25

Applicant: AMGEN INC.

Inventor： Cen XU ,  Agnes Eva HAMBURGER

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61P25/06 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

公开(公告)号：US20180334488A1

公开(公告)日：2018-11-22

申请号：US16008686

申请日：2018-06-14

Applicant: VIB VZW ,  UNIVERSITEIT GENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER 2 ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER

Inventor： Jan TAVERNIER ,  Lennart ZABEAU ,  Gilles UZE ,  Franciane PAUL ,  Yann BORDAT ,  Genevieve GARCIN

IPC: C07K14/56 ,  C07K16/28

CPC classification number: C07K14/56 ,  C07K16/2869 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/33 ,  C07K2319/74

Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.

公开(公告)号：US20180273585A1

公开(公告)日：2018-09-27

申请号：US15924669

申请日：2018-03-19

Applicant: ValiRx PLC

Inventor： Mark Eccleston ,  Satu Vainikka ,  George Steven Morris

IPC: C07K7/06 ,  C07K16/18 ,  A61K47/64 ,  C07K5/097 ,  C07K5/117 ,  G01N33/68 ,  C07K16/28 ,  C07K7/08 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K47/643 ,  A61K47/646 ,  C07K5/0821 ,  C07K5/1024 ,  C07K7/08 ,  C07K16/18 ,  C07K16/2869 ,  G01N33/689 ,  G01N2333/723 ,  G01N2500/02 ,  G01N2800/364

Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject. Preferably, the molecule comprises or consists of the structure: Bj-[(Pro)n-XrHis-Pro-His-Ala-Arg-Ile-Lys]m-Rp, or Bj-[lys-ile-arg-ala-his-pro-his-xr-(pro)n]m-Rp, or a derivative or fragment thereof, wherein B is a first chemical moiety, j is 0 or 1, n is an integer from 1-10, X is any amino acid, r is an integer from 0 to 2, m is an integer from 1 to 3, R is a second chemical moiety, p is 0 or 1, and [lys-ile-arg-ala-his-pro-his-xr-(pro)n] is the retro-inverso peptide of [(Pro)n-Xr-His-Pro-His-Ala-Arg-Ile-Lys].

公开(公告)号：US20180237533A1

公开(公告)日：2018-08-23

申请号：US15752195

申请日：2016-08-24

Applicant: CELLECTIS

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/72 ,  A61P35/00

CPC classification number: C07K16/2869 ,  A61K31/436 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/721 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.

公开(公告)号：US10053507B2

公开(公告)日：2018-08-21

申请号：US15592115

申请日：2017-05-10

Applicant: AMGEN INC.

Inventor： Cen Xu ,  Agnes Eva Hamburger

IPC: A61K35/12 ,  A61K39/00 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61P25/06 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

公开(公告)号：US20180186894A1

公开(公告)日：2018-07-05

申请号：US15901545

申请日：2018-02-21

Applicant: VIB VZW ,  UNIVERSITEIT GENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ MONTPELLIER 2 ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER

Inventor： Jan Tavernier ,  Sarah Gerlo ,  Frank Peelman ,  Gilles Uze

IPC: C07K16/40 ,  C07K16/32 ,  C07K14/545 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/2869 ,  C07K16/32 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2319/00

Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.